Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00511043 · ClinicalTrials.gov registry record · Phase 2
PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma
A Phase 2 study, sponsored by David Rizzieri, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00511043 is a Phase 2 study that was terminated before completion, run by David Rizzieri, MD. The registered enrollment target is 20 participants.
The verdict
NCT00511043, a Phase 2 study, was terminated before completion, sponsored by David Rizzieri, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a phase II open label study to assess the efficacy and safety of PTK787/ZK222584 in adults with relapsed or refractory diffuse large cell lymphoma (DLCL). All subjects will receive PTK787/ZK222584. Subjects who tolerate the study target dose of 1250mg will remain on that dose until study completion at 12 months or until disease progression, unacceptable toxicity, withdrawal of consent or non-compliance with the protocol requirement.
Interventions
- DRUG PTK787
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-11 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00511043
The ClinicalTrials.gov registry entry for NCT00511043 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is David Rizzieri, MD, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PTK787 is the first listed.
NCT00511043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00511043 about?
NCT00511043 is a clinical study titled "PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma". This is a phase II open label study to assess the efficacy and safety of PTK787/ZK222584 in adults with relapsed or refractory diffuse large cell lymphoma (DLCL). All subjects will receive PTK787/ZK222584. Subjects who tolerate the study target dose of 1250mg will remain on that dose until study com...
What is the current status of trial NCT00511043?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2005-11. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00511043?
The interventions under investigation include: PTK787 (DRUG).
Who is sponsoring clinical trial NCT00511043?
This trial is sponsored by David Rizzieri, MD, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.